Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study [PDF]
Multiple Sclerosis Journal, 2023 BACKGROUND: Diroximel fumarate (DRF) is approved for adults with relapsing-remitting multiple sclerosis (RRMS) in Europe and for relapsing forms of MS in the United States.
Jiwon Oh +2 more
exaly +4 more sources
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study [PDF]
Advances in Therapy, 2022 INTRODUCTION: Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis (MS) with the same active metabolite as dimethyl fumarate (DMF).
Annette Wundes +2 more
exaly +6 more sources
Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study [PDF]
Multiple Sclerosis Journal, 2020 BACKGROUND: Diroximel fumarate (DRF) is a novel oral fumarate for patients with relapsing-remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield bioequivalent exposure to the active metabolite monomethyl fumarate; thus ...
Catherine Taylor +2 more
exaly +4 more sources
Descriptive Analysis of Patients Treated with Diroximel Fumarate and Dimethyl Fumarate—A Real-Life Experience [PDF]
Journal of Personalized MedicineBackground: Dimethyl fumarate (DMF) and diroximel fumarate (DRF) are two treatments used for multiple sclerosis (MS) that have been shown to be effective in controlling MS patients.
Marina Blanco-Ruiz +1 more
exaly +3 more sources
Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility? [PDF]
Pharmaceuticals, 2020 Fumaric acid esters (FAEs) are small molecules with anti-oxidative, anti-inflammatory and immune-modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing ...
Stephanie Kourakis +5 more
doaj +4 more sources
Pharmaceuticals, 2022 Dimethyl fumarate (DMF) has emerged as a first-line therapy for relapsing-remitting multiple sclerosis (RRMS). This treatment, however, has been limited by adverse effects, which has prompted development of novel derivatives with improved tolerability ...
William R. Swindell +2 more
doaj +2 more sources
Brain DisordersObjective: Dimethyl fumarate (DMF) and diroximel fumarate (DRF) are oral multiple sclerosis (MS) disease-modifying therapies (DMTs). Absolute lymphocyte count (ALC) dynamics are similar for DMF and DRF, but have not been investigated in patients who ...
Shauna M. Gales +9 more
doaj +2 more sources
Predictors of high- versus low-intensity first-line multiple sclerosis treatments [PDF]
Multiple Sclerosis Journal - Experimental, Translational and ClinicalBackground Disease-modifying therapies (DMTs) for multiple sclerosis (MS) can be either high- or low-intensity. This study aims to examine predictors associated with high-intensity MS treatment strategies using commercial claims data.
Amanda V. Gusovsky Chevalier +5 more
doaj +2 more sources
Diagnoses of Multiple Sclerosis and Related Disorders and Disease-Modifying Therapies: A Comparison of the Danish Multiple Sclerosis Registry With Other Danish Health Registries. [PDF]
Brain BehavThis study aimed to describe and compare information on diagnoses of MS and related disorders as well as treatments with disease‐modifying therapies (DMTs) available in three national registries, highlighting the key differences relevant to MS research.
Joensen H +3 more
europepmc +2 more sources
Fumarate-based drugs protect against neuroinflammation via upregulation of anti-ferroptotic pathways [PDF]
Journal of NeuroinflammationFerroptosis is defined as iron dependent non-apoptotic cell death. It is based on peroxidation of polyunsaturated phospholipids and subsequent membrane rupture.
Katinka Fischer +10 more
doaj +2 more sources